WASHINGTON, Aug. 26 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to R3 Medical Companies from its Center for Biologics Evaluation and Research:

* * *

Recipient: David L. Greene, M.D., Chief Executive Officer, R3 Medical Companies, 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, United States, dgreene@bello.bio, dgreene@regensuppliers.com

Issuing Office: Center for Biologics E . . .

Click here for more information about our products